The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial

被引：86
作者：
Seebacher, V. [1 ]
Polterauer, S. [1 ]
Grimm, C. [1 ]
Husslein, H. [2 ]
Leipold, H. [2 ]
Hefler-Frischmuth, K. [3 ]
Tempfer, C. [1 ]
Reinthaller, A. [1 ]
Hefler, L. [1 ]
机构：
[1] Med Univ Vienna, Dept Obstet & Gynaecol, A-1090 Vienna, Austria
[2] Landeskrankenhaus Klagenfurt, Dept Obstet & Gynaecol, Carinthia, Austria
[3] Wilhelminenspital Stadt Wien, Dept Lab Med, A-1160 Vienna, Austria
来源：
BRITISH JOURNAL OF CANCER | 2010年 / 102卷 / 06期
关键词：
fibrinogen; endometrial cancer; prognosis; C-REACTIVE PROTEIN; LYMPHATIC METASTASIS; TUMOR STROMA; GROWTH; CELLS; ASSOCIATION; CARCINOMA; HYPERFIBRINOGENEMIA; BIOSYNTHESIS; CYTOTOXICITY;
D O I：
10.1038/sj.bjc.6605547
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BACKGROUND: To analyse the correlation between pre-treatment plasma fibrinogen levels and clinical-pathological parameters in patients with endometrial cancer and to assess the value of plasma fibrinogen as a prognostic parameter. METHODS: Within a retrospective multi-centre study, the records of 436 patients with endometrial cancer were reviewed and pre-treatment plasma fibrinogen levels were correlated with clinical-pathological parameters and patients' survival. RESULTS: The mean (s.d.) pre-treatment plasma fibrinogen level was 388.9 (102.4) mg per 100 ml. Higher plasma fibrinogen levels were associated with advanced tumour stage (FIGO I vs II vs III and IV, P = 0.002), unfavourable histological subtype (endometrioid vs non-endometrioid histology, P = 0.03), and higher patients' age (<= 67 years vs > 67 years, P = 0.04), but not with higher histological grade (G1 vs G2 vs G3, P = 0.2). In a multivariate analysis, tumour stage (P < 0.001 and P < 0.001), histological grade (P = 0.009 and P = 0.002), patients' age (P = 0.001 and P < 0.001), and pre-treatment plasma fibrinogen levels (P 0.04 and P = 0.02) were associated with disease-free and overall survival, respectively. CONCLUSION: Plasma fibrinogen levels can be used as an independent prognostic parameter for the disease-free and overall survival of patients with endometrial cancer. British Journal of Cancer (2010) 102, 952-956. doi:10.1038/sj.bjc.6605547 www.bjcancer.com Published online 16 February 2010 (C) 2010 Cancer Research UK
引用
收藏
页码：952 / 956
页数：5
相关论文
共 41 条
[1]   The plasminogen activation system in tumor growth, invasion, and metastasis [J].
Andreasen, PA ;
Egelund, R ;
Petersen, HH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (01) :25-40
[2]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[3]  
Bardos H, 1996, BLOOD COAGUL FIBRIN, V7, P536
[4]   Soluble fibrin inhibits lymphocyte adherence and cytotoxicity against tumor cells: Implications for cancer metastasis and immunotherapy [J].
Biggerstaff, John P. ;
Weidow, Brandy ;
Dexheimer, Judith ;
Warnes, Gary ;
Vidosh, Jacqueline ;
Patel, Shonak ;
Newman, Michael ;
Patel, Pretesh .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2008, 14 (02) :193-202
[5]   Soluble fibrin inhibits monocyte adherence and cytotoxicity against tumor cells: Implications for cancer metastasis [J].
Biggerstaff J.P. ;
Weidow B. ;
Vidosh J. ;
Dexheimer J. ;
Patel S. ;
Patel P. .
Thrombosis Journal, 4 (1)
[6]  
BROWN LF, 1988, AM J PATHOL, V130, P455
[7]  
CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
[8]  
COSTANTINI V, 1991, CANCER RES, V51, P349
[9]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[10]  
Creasman W T, 2001, J Epidemiol Biostat, V6, P47
12345